drugset / Trial / NCT03306394

A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).

NCT03306394

Phase 3 Completed 907 enrolled Servier ADIR, a Servier Group company · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to collect additional safety and efficacy data during treatment with trifluridine / tipiracil in patients with a pretreated metastatic colorectal cancer (mCRC). Eligible patients may receive an early access to trifluridine / tipiracil through this clinical study until progression of disease, unacceptable toxicity, investigator decision, patient refusal or until market authorization or reimbursement has been granted by the relevant Authority of the country where that patient is treated or until trifluridine / tipiracil is available by a doctor's prescription or can be accessed from another source or Sponsor decision.

Timeline

Start
2016-10-18
Primary completion
2020-11-30
Completion
2020-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Tipiracil Small molecule 7.065 mg Oral
Subject Tipiracil Small molecule 9.42 mg Oral
Subject Trifluridine Small molecule 15 mg Oral
Subject Trifluridine Small molecule 20 mg Oral

Indications